imatinib (Samyang)

伊马替尼 (Samyang)

Report date: 2025/04/29 13:26:01

Base Information

Drug Nameimatinib (Samyang)
Drug Alias NameSYO-1126
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsBcr-Abl tyrosine kinase inhibitorsStem cell growth factor receptor inhibitors
TargetsPlatelet-derived growth factor receptorBcr-Abl tyrosine kinaseStem cell growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSamyang Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSamyang Corp
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A